Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.60 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22427804 | 0.79 | KDM4E (0.43) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL11534549 | 0.75 | KDM4E (1.00) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL13325866 | 0.75 | ALDH1A1 (0.77) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL14630027 | 0.74 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL23246964 | 0.74 | KDM4E (0.55) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL15833696 | 0.74 | CYP1A2 (0.40) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL20674503 | 0.74 | KDM4E (0.55) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL10207538 | 0.74 | KDM4E (0.58) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL3538954 | 0.74 | KDM4E (0.55) | ALDH1A1KDM4EMAPTTDP1CHEK1 | |
| SCHEMBL334476 | 0.74 | KDM4E (0.55) | ALDH1A1KDM4EMAPTTDP1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| WO-2024092069-A1 | CXCR4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL DISEASES | X4 PHARMACEUTICALS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-7541362-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1261607-B1 | 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| US-20070244179-A1 | Dihydro[1,4]dioxino[2,3-e]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070120111-A1 | Organic thin film transistor | IDEMITSU KOSAN CO., LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070120111-A1 | Organic thin film transistor | IDEMITSU KOSAN CO., LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| US-4409226-A | ANTIULCER AGENTS | SCHERING CORPORATION (US) | 1983-10-11 | — | — | US | disclosed |
| US-4361567-A | IMIDAZO(1,5-A)PYRIDINES | SCHERING CORPORATION (US) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | ALDH1A1 1192/4885KDM4E 1116/4885MAPT 992/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | ALDH1A1 587/4885KDM4E 3565/4885MAPT 3782/4885 |
| US-20070244179-A1 | Dihydro[1,4]dioxino[2,3-e]indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR3A | ALDH1A1 508/4885KDM4E 2820/4885MAPT 1575/4885 |
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | ALDH1A1 3301/4885KDM4E 977/4885MAPT 3283/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | ALDH1A1 2920/4885KDM4E 3048/4885MAPT 2176/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ALDH1A1 344/4885KDM4E 2800/4885MAPT 2188/4885 |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | ALDH1A1 3301/4885KDM4E 977/4885MAPT 3283/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ALDH1A1 344/4885KDM4E 2800/4885MAPT 2188/4885 |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | ALDH1A1 3301/4885KDM4E 977/4885MAPT 3283/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ALDH1A1 312/4885KDM4E 2437/4885MAPT 2516/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | ALDH1A1 3301/4885KDM4E 977/4885MAPT 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.